CLLS (Cellectis) Buildings And Improvements: $53.01 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLLS Cellectis SA CLLS
58 GF Score
Price $3.24
GF Value $3.02
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Cellectis Buildings And Improvements?

Cellectis CLLS -2.85% 58 Buildings And Improvements is $53.01 Mil as of Jun. 2026. GuruFocus rates CLLS with a GF Score™ of 58/100 and a GF Value™ of $3.02 (Fairly Valued). The stock has 5 warning signs investors should review.

Cellectis's quarterly buildings and improvements declined from Dec. 2025 ($53.75 Mil) to Mar. 2026 ($53.23 Mil) and declined from Mar. 2026 ($53.23 Mil) to Jun. 2026 ($53.01 Mil).

Cellectis's annual buildings and improvements declined from Dec. 2023 ($51.86 Mil) to Dec. 2024 ($50.91 Mil) but then increased from Dec. 2024 ($50.91 Mil) to Dec. 2025 ($53.75 Mil).

Cellectis Buildings And Improvements Historical Data

* Premium members only.

The historical data trend for Cellectis's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellectis Buildings And Improvements Chart

Cellectis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buildings And Improvements
Get a 7-Day Free Trial Premium Member Only Premium Member Only 69.78 49.42 51.86 50.91 53.75

Cellectis Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Buildings And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.69 53.74 53.75 53.23 53.01
CLLS
58GF Score
Cellectis SA CLLS
Buildings And Improvements is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cellectis Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.

What does a Buildings And Improvements of $53.01 Mil mean?
Cellectis (CLLS) has a Buildings And Improvements of $53.01 Mil as of Jun. 2026. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on Cellectis and its competitors.
Is Cellectis' Buildings And Improvements too high?
Cellectis' current Buildings And Improvements is $53.01 Mil. Overall, Cellectis has a GF Score™ of 58/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cellectis' Buildings And Improvements compare to VRTX and REGN?
Cellectis' Buildings And Improvements of $53.01 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buildings And Improvements for a Biotechnology company?
A good Buildings And Improvements depends on the Biotechnology industry context. However, Buildings And Improvements should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buildings And Improvements mean?
A high Buildings And Improvements can signal that a stock is expensive relative to its fundamentals. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on Cellectis and its competitors. Cellectis's current Buildings And Improvements is $53.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellectis stock overvalued right now?
Based on GuruFocus' analysis, Cellectis (CLLS) is currently considered Fairly Valued. The stock's GF Value™ is $3.02, compared to a current price of $3.24 — trading 7.3% above its estimated fair value. The current Buildings And Improvements is $53.01 Mil. Cellectis' overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buildings And Improvements calculated?
Buildings And Improvements is calculated from a company's financial statements. For Cellectis (CLLS), the current Buildings And Improvements is $53.01 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cellectis (CLLS) Overvalued in 2026?

Based on GuruFocus' analysis, Cellectis stock appears to be overvalued. The current stock price of $3.24 is trading 7.3% above its estimated GF Value™ of $3.02. GuruFocus considers Cellectis to be Fairly Valued.

Key valuation signals for CLLS:

  • Buildings And Improvements: $53.01 Mil
  • GF Value™: $3.02 vs. price of $3.24 (7.3% above fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the CLLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cellectis Business Description

Address 8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
58GF Score

Get the complete analysis for CLLS

Buildings And Improvements is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.24
Price
$3.02
GF Value